This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Guillain-Barré syndrome (acute inflammatory demyelinating polyneuropathy)Guillain-Barré Syndrome (GBS / Acute Inflammatory Demyelinating Polyneuropathy)

Contents and key points
ItemDetails
A. Classification codesICD-10: G61.0 | Special Copayment Reduction: V126 | Coverage period: 5 years
B. SynonymsGuillain-Barré syndrome, acute inflammatory demyelinating polyneuropathy (AIDP), Miller Fisher syndrome (GQ1b antibody positive; triad of ophthalmoplegia, ataxia, and areflexia), acute motor axonal neuropathy (AMAN)
C. Adult onsetHigh likelihood of first onset in adulthood — occurs at all ages, but incidence peaks at 50–75 years; acute onset 2–4 weeks after a preceding infection
1. HistoryReported by Guillain, Barré, and Strohl in 1916; described albuminocytologic dissociation and loss of reflexes; pathophysiology later established through subtype classification and discovery of antiganglioside antibodies
2. CausesAfter preceding infection with Campylobacter jejuni (~30%), CMV, EBV, Zika, or SARS-CoV-2, an autoimmune response is triggered through molecular mimicry
3. GeneticsNonhereditary autoimmune disease; genetic susceptibility factors such as HLA and FcγR polymorphisms under study; no familial risk
4. General epidemiologyIncidence 1–2/100,000/year; about 100,000 people worldwide per year; 1.5 times more common in men; AIDP (predominant in the West), AMAN (predominant in East Asia)
5. PathophysiologyMolecular mimicry → antiganglioside antibodies → complement activation → demyelination (AIDP) or axonal injury at the nodes of Ranvier (AMAN); GQ1b antibodies cause MFS
6. SymptomsAscending symmetric limb weakness, sensory disturbances, neuropathic pain (~90%), autonomic dysfunction (arrhythmia, blood pressure fluctuation), respiratory failure (mechanical ventilation in about 30%)
7. SignsLoss of tendon reflexes (universal from early on), symmetric limb weakness, bilateral facial palsy, autonomic instability, reduced respiratory function (decreased FVC)
8. ScreeningClinical suspicion from the combination of acutely progressive symmetric weakness + areflexia; Brighton diagnostic criteria; monitor respiratory function (FVC) every 6 hours
9. DiagnosisCerebrospinal fluid (albuminocytologic dissociation), nerve conduction studies (demyelinating or axonal pattern), antiganglioside antibodies (GQ1b, GM1, GD1a), spinal MRI
10. TreatmentIVIG (2 g/kg/5 days) or plasma exchange (5 sessions) equally effective; no added benefit from combination; steroids alone ineffective; intensive respiratory and autonomic management
11. PrognosisAbout 80% regain independent walking within 6 months; mortality 3–5%; recurrence 2–5%; poor prognosis: older age, C. jejuni, reduced CMAP amplitude, mechanical ventilation
12. PreventionNo specific prevention; prevent C. jejuni through food hygiene; minimize long-term disability with early rehabilitation; individualized risk-benefit counseling on vaccination
References10 key references (including PMID/DOI)

1. History

Guillain-Barré syndrome (GBS) was first systematically described in 1916, when the French neurologists Georges Guillain, Jean Alexandre Barré, and André Strohl reported in the medical literature cases of acute ascending paralysis observed in 2 soldiers during World War I. They identified as key clinical features the so-called "albuminocytologic dissociation"—a markedly elevated protein concentration in the cerebrospinal fluid with a cell count in the normal range—and loss of deep tendon reflexes. Earlier, in 1859, Jean-Baptiste Landry had reported acute ascending paralysis with a similar clinical course, and the name "Landry's ascending paralysis" has also been used historically.

Until the mid-20th century, GBS was regarded as a single disease, but from the 1980s onward, with the spread of nerve conduction studies, AIDP (acute inflammatory demyelinating polyneuropathy) was shown to be the main subtype in the West. At the same time, in the 1990s it became clear that in Asia, including China and Japan, there is a separate AMAN (acute motor axonal neuropathy) subtype with a pattern of pure motor axonal injury. In 1956, Miller Fisher reported a distinctive subtype characterized by the triad of external ophthalmoplegia, ataxia, and areflexia, and after the 1990s, when anti-GQ1b IgG antibodies were found to be specifically detected in this subtype, understanding of the subtype-specific pathophysiology of GBS advanced dramatically. In terms of treatment, the 1992 randomized controlled trial of the Dutch GBS Study Group demonstrated that IVIG and plasma exchange are equally effective, and multiple large clinical trials confirmed that steroid monotherapy is ineffective. The International GBS Outcome Study (IGOS) cohort, begun in the 2010s, is still ongoing and is exploring new treatment strategies and prognostic factors.

2. Causes

GBS is a nonhereditary acquired autoimmune disease that mostly occurs 2–4 weeks after a preceding infection. Molecular mimicry is the key causal mechanism: structural similarity between pathogen antigens and peripheral nerve gangliosides is understood to trigger a cross-reactive immune response. Depending on the type of preceding infection, the GBS subtype that develops and the type of antiganglioside antibody involved may differ.

3. Genetics

GBS is not a genetic disease with Mendelian inheritance and is not explained by a single gene mutation. Clinically, familial clustering is very rare. However, the fact that only a tiny fraction (about 0.1%) of people infected with C. jejuni develop GBS suggests that host genetic factors play an important role in determining disease onset. Research on genetic susceptibility is therefore ongoing.

The main genetic factors under study include HLA alleles (some studies report associations of HLA-B*35, HLA-DQ2, HLA-DR2, and others with GBS risk), Fcγ receptor (FcγR) polymorphisms (in particular, the FcγRIIa-H131 polymorphism may be associated with post-Campylobacter AMAN), and TLR (Toll-like receptor) polymorphisms (which affect the strength of the innate immune response). However, these associations are inconsistent across ethnic groups and subtypes, and predicting GBS risk through genetic testing is currently not clinically possible. Studies identifying susceptibility genes through genome-wide association studies (GWAS) are underway at the level of international consortia, exploring the future possibility of personalized risk prediction.

4. General epidemiology

GBS is the most common cause of acquired neuromuscular paralysis worldwide. The annual incidence is about 1.0–2.0 per 100,000 population, with reports ranging from 0.6 to 4 depending on region and study methodology. About 100,000 people worldwide are estimated to be affected each year. Incidence rises with age, peaking at 50–75 years. It also occurs in children, who tend to recover faster and have a better prognosis than adults.

In terms of sex, men have an incidence about 1.5 times higher than women, and this sex difference is consistently observed across all age groups. Regional differences by subtype are pronounced: the AIDP subtype accounts for about 90% in Western countries, whereas the AMAN subtype shows a relatively high proportion (20–30%) in East Asia (China, Japan, Korea). The seasonality of AMAN matches the epidemic pattern of C. jejuni infection, tending to cluster in summer to early autumn. Miller Fisher syndrome (MFS) accounts for about 5% of all GBS (about 15–25% in East Asia). In Korea, AIDP is the main subtype, but an epidemiological feature is that the proportions of AMAN and MFS are relatively higher than in the West.

5. Pathophysiology

The pathogenesis of GBS is an autoimmune response triggered after a preceding infection, with molecular mimicry as the core concept. Epitopes of pathogen surface antigens are structurally similar to peripheral nerve gangliosides, so antibodies produced in response to infection cross-target nerve tissue. The mechanisms by subtype are as follows.

Mechanism of AIDP (demyelinating form): T-cell- and antibody-mediated immune responses target Schwann cells and myelin. Antibodies and complement are activated on the myelin, forming the membrane attack complex (MAC), after which macrophages infiltrate and phagocytose and destroy the myelin. Damage begins around the nodes of Ranvier and at the nerve root level, producing conduction block. The exact target antigens have not yet been fully identified; P0, P2 proteins, and others are being studied.

Mechanism of AMAN (axonal form): Anti-GM1 or anti-GD1a IgG antibodies bind to the nodes of Ranvier of motor nerve axons. Complement activation then forms the membrane attack complex, damaging the axonal membrane at the nodes. Because Schwann cells are relatively preserved, recovery may be rapid in mild cases, but when axonal transection (wallerian degeneration) occurs, recovery is delayed or incomplete. Infiltration of macrophages into the nodes of Ranvier is a pathological hallmark.

Mechanism of MFS (Miller Fisher subtype): Anti-GQ1b IgG antibodies are specifically observed (sensitivity ~90%). GQ1b ganglioside is highly expressed at the nodes of Ranvier of the oculomotor nerves (cranial nerves III, IV, and VI) and in the Ia afferent fibers of muscle spindles, which is thought to explain how this antibody causes external ophthalmoplegia, ataxia, and areflexia.

Mechanism of autonomic involvement: Direct involvement of sympathetic and parasympathetic preganglionic and postganglionic fibers causes cardiac arrhythmias, blood pressure fluctuations, sweating abnormalities, and bladder and bowel dysfunction. This is one of the main causes of death in GBS.

6. Symptoms

GBS typically has an acute onset 2–4 weeks after a preceding infection, and most patients reach maximal weakness (nadir) within 4 weeks. If progression continues beyond 4 weeks, subacute inflammatory demyelinating polyneuropathy (SIDP) or CIDP must be differentiated. The main symptom domains are as follows.

Motor symptoms: Symmetric ascending limb weakness that begins in the legs and progresses to the arms, trunk, and cranial nerves is typical. In the most severe patients (about 25–30%), respiratory muscle involvement necessitates mechanical ventilation. Bulbar nerve involvement causes dysphagia, dysarthria, and facial muscle weakness. Descending progression is atypical.

Sensory symptoms: Distal limb tingling, paresthesia, and neuropathic pain occur in about 90% and may be prominent early on. Incoordination due to impaired proprioception (sensory ataxia) may occur. In the pure motor form (AMAN), sensory symptoms are mild or absent.

Autonomic symptoms: Heart rate fluctuations (tachycardia/bradycardia), blood pressure instability (orthostatic hypotension, paroxysmal hypertension), sweating abnormalities, facial flushing, urinary retention, decreased bowel motility (constipation or diarrhea), and rarely abnormal pupillary responses occur. Autonomic dysfunction is a major indication for ICU admission.

Cranial nerve symptoms: Bilateral facial nerve palsy (about 50%), often occurring asymmetrically. Dysphagia, dysarthria (glossopharyngeal and vagus nerve involvement), and diplopia (external ophthalmoplegia; prominent in the MFS subtype) may occur. Bickerstaff brainstem encephalitis is also accompanied by altered consciousness.

7. Signs

The major signs on physical examination are central to diagnosis and provide the basis for clinical suspicion of GBS.

Tendon reflex abnormalities: Loss or reduction of deep tendon reflexes is a near-universal sign of GBS, present from early in the illness; reflexes are lost first distally (ankle reflex), and with progression all tendon reflexes are lost. Preserved reflexes cast doubt on the diagnosis of GBS.

Pattern of weakness: Symmetric weakness is typical and is assessed with the MRC scale. Marked asymmetric weakness requires differential diagnosis of vascular lesions, other neuropathies, and similar conditions.

Respiratory function: Mechanical ventilation should be actively considered when the "20-30-40 rule" is met: forced vital capacity (FVC) below 20 mL/kg, maximal inspiratory pressure (MIP) below -30 cmH2O, or maximal expiratory pressure (MEP) below 40 cmH2O. Oxygen saturation is a late indicator of respiratory failure and is unreliable on its own.

Autonomic signs: Arrhythmias (tachycardia/bradycardia), blood pressure fluctuations, excessive sweating, bladder distension, and other signs may be observed. Severe autonomic dysfunction is a major cause of death in GBS and requires continuous ECG monitoring.

Cranial nerve signs: Systematically check for bilateral facial palsy (House-Brackmann grade), restricted eye movements (especially in MFS), loss of the gag reflex, tongue weakness, and other signs.

8. Screening

Because GBS is a clinically diagnosed disease, clinical suspicion takes precedence over screening tests. In patients with the combination of acutely progressive symmetric limb weakness and loss of tendon reflexes, GBS should be considered promptly and diagnostic testing begun.

Brighton Collaboration diagnostic criteria: Level 1 (highest certainty): all of bilateral limb weakness + areflexia + CSF albuminocytologic dissociation + nerve conduction abnormalities are met. Level 2: either nerve conduction or CSF findings met. Level 3: only clinical criteria met (test results not available).

Emergency screening indicators: Monitor the rate of worsening weakness within 24–48 hours of symptom onset, signs of autonomic instability (for decisions on ICU transfer), FVC measured at least every 6 hours after admission, and swallowing function (aspiration risk assessment). In particular, immediate ICU transfer should be considered if FVC declines rapidly or if dysarthria or dysphagia develops.

Early assessment of prognostic indicators: The EGOS (Erasmus GBS Outcome Score) or mEGOS is useful at week 2 for predicting independent walking at 6 months and is used as a basis for planning intensive rehabilitation.

9. Diagnosis

The diagnosis of GBS integrates clinical, electrophysiological, cerebrospinal fluid, and serological testing. No single test confirms the diagnosis, and a combined judgment is required.

Cerebrospinal fluid examination (lumbar puncture): Albuminocytologic dissociation is the typical finding: elevated protein (generally ≥45 mg/dL, often ≥100 mg/dL) with a normal cell count (below 10/μL). Protein may be normal within 1 week of symptom onset, so testing is repeated after 1–2 weeks if needed. Pleocytosis calls for differential diagnosis of HIV neuropathy, Lyme disease, CMV meningitis, and others.

Nerve conduction studies (NCS) and electromyography (EMG): Essential for GBS subtype classification and prognosis. AIDP: reduced conduction velocity, prolonged distal latency, delayed or absent F waves, conduction block. AMAN: preserved conduction velocity, reduced CMAP amplitude, normal sensory nerve conduction. Abnormalities are mild early on (within 1 week), so repeat testing after 1–2 weeks may be needed.

Antiganglioside antibody testing: Anti-GQ1b IgG (sensitivity ~90% for MFS), anti-GM1 IgG (associated with AMAN), anti-GD1a IgG (associated with AMAN), anti-GD1b IgG (associated with sensory-predominant GBS). Panel testing is used for subtype classification and prognosis.

MRI: Gadolinium enhancement of spinal nerve roots (mainly the anterior roots) may be observed, and MRI is useful for differentiating GBS-like conditions such as spinal cord compression and neoplastic meningitis. Brain MRI is used to differentiate Bickerstaff brainstem encephalitis.

Other tests: C. jejuni culture and serum antibodies, HIV, EBV, and CMV serology, autonomic function testing (heart rate variability), pulmonary function testing (FVC, MIP, MEP).

10. Treatment

Immunotherapy: IVIG and plasma exchange (PE) are the standard immunotherapies for GBS and are equally effective. Both shorten ongoing weakness, reduce the duration of mechanical ventilation, and promote functional recovery.

Supportive and intensive care: Includes respiratory monitoring (early intubation if FVC <15–20 mL/kg or with rapid progression), autonomic management (continuous ECG monitoring, treatment of blood pressure fluctuations), treatment of neuropathic pain (gabapentin, carbamazepine, tricyclic antidepressants), deep vein thrombosis prophylaxis (LMWH and compression stockings), nutritional support (nasogastric tube or gastrostomy for dysphagia), pressure ulcer prevention, and early initiation of physical therapy.

Novel treatments under investigation: The efficacy of eculizumab (a complement C5 inhibitor) in GBS is being tested in small randomized controlled trials. A second IVIG dose regimen for IVIG-refractory cases is also being studied, and as of 2025 no new standard treatment has been established.

11. Prognosis

The clinical course of GBS is mostly monophasic, with gradual recovery after treatment. However, some patients are left with long-term disability. The course of recovery varies greatly by subtype and individual characteristics.

Course of recovery: About 80–85% of patients regain independent walking within 6 months. After reaching maximal weakness (nadir), there is a plateau phase followed by gradual recovery over weeks to months. AIDP requires months for remyelination; mild AMAN can recover rapidly, but recovery is slow and incomplete with severe axonal transection.

Poor prognostic factors: Older age (65 years or older), preceding C. jejuni infection, severe reduction or loss of CMAP amplitude, rapid progression within 4 weeks and need for mechanical ventilation, and a high-risk EGOS (Erasmus GBS Outcome Score) or mEGOS are associated with poor prognosis.

Long-term outcomes and complications: Mortality is about 3–5%, mainly due to ICU complications (pneumonia, pulmonary embolism, sepsis) in patients on mechanical ventilation. Residual disability at 1 year (inability to walk independently) occurs in about 15–20%. Recurrence (RGBS) occurs in about 2–5% of all cases, and differentiation from CIDP is important when it recurs. Treatment-related fluctuations (TRF) after IVIG occur in about 8–16%, and additional treatment is considered. Chronic fatigue and neuropathic pain have a major impact on long-term quality of life.

12. Prevention

No method for specifically preventing GBS has currently been established. Prevention strategies focus mainly on preventing preceding infections, early detection, and minimizing long-term disability.

Infection prevention: Food hygiene to prevent food poisoning from Campylobacter and other organisms (thorough cooking of poultry, hygienic handling, prevention of cross-contamination) is important. Safe drinking water and food habits are recommended to prevent traveler's diarrhea. General hygiene measures to prevent respiratory virus infections (influenza, CMV, etc.) may also help.

Vaccine-related considerations: The risk of GBS after influenza vaccination is very low (about 1–2 cases per 1 million doses), and the risk of GBS from influenza infection itself is much higher than the risk after vaccination. Therefore, a prior history of GBS alone does not require contraindicating influenza vaccination, but vaccination within 6 weeks of GBS onset is avoided. For patients with a history of GBS, it is recommended that the need for and risks of vaccination be discussed and decided individually.

Early detection and rehabilitation: Educate patients to seek immediate neurological evaluation if acutely progressive limb weakness develops. Early physical therapy, occupational therapy, and swallowing rehabilitation improve long-term functional recovery and quality of life. A multidisciplinary rehabilitation approach that includes pain management and psychological support (high risk of comorbid depression and anxiety) is needed.

References

  1. Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. Lancet. 2016;388(10045):717-727. DOI: 10.1016/S0140-6736(16)00339-1
  2. Bellanti R, et al. Guillain-Barré syndrome: a comprehensive review. Eur J Neurol. 2024;31(11):e16365. DOI: 10.1111/ene.16365
  3. van den Berg B, Walgaard C, Drenthen J, et al. Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol. 2014;10(8):469-482. PMID: 25023340
  4. Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2014;9:CD002063. PMID: 25238327
  5. Chevret S, et al. Plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2017;2:CD001798. PMID: 28241090
  6. Jacobs BC, van den Berg B, Verboon C, et al. International Guillain-Barré Syndrome Outcome Study: protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome. J Peripher Nerv Syst. 2017;22(4):321-328. PMID: 28512919
  7. Fokke C, van den Berg B, Drenthen J, et al. Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria. Brain. 2014;137(1):33-43. PMID: 24163275
  8. Leonhard SE, Mandarakas MR, Gondim FAA, et al. Diagnosis and management of Guillain-Barré syndrome in ten steps. Nat Rev Neurol. 2019;15(11):671-683. PMID: 31541214
  9. Doets AY, Verboon C, van den Berg B, et al. Regional variation of Guillain-Barré syndrome. Brain. 2018;141(10):2866-2877. PMID: 30107501
  10. Walgaard C, Lingsma HF, Ruts L, et al. Early recognition of poor prognosis in Guillain-Barré syndrome. Neurology. 2011;76(11):968-975. PMID: 21403110